# Savolitinib vs. Sunitinib in MET-driven PRCC.

> **NCT03091192** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 60 (actual)

## Conditions studied

- Carcinoma
- Carcinoma, Renal Cell
- Kidney Neoplasms
- Urologic Neoplasms
- Kidney Diseases
- Neoplasms by Site
- Enzyme Inhibitors
- Protein Kinase Inhibitors

## Interventions

- **DRUG:** Savolitinib
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT03091192
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-07-25
- **Primary completion:** 2019-08-18
- **Final completion:** 2026-12-31
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03091192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03091192, "Savolitinib vs. Sunitinib in MET-driven PRCC.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03091192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*